Our resource hub is home to a wealth of articles, stories and videos about managing and living with type 1 diabetes.
Place your order for our free information packs that support adults and children who have been recently diagnosed.
Our researchers are working on different ways to develop a cure for type 1 diabetes - from growing insulin-producing beta cells in labs to hacking the immune system.
Learn about the technologies that can deliver insulin automatically when needed. And discover the next generation of insulins that are currently being developed.
We have a wide range of fun and festive designs to choose from. Fund life changing research while spreading joy this Christmas!
This Christmas, your gift can bring us closer to a cure for type 1 diabetes – and every pound you give to our Christmas Appeal will be doubled.
The announcement is the biggest treatment breakthrough for type 1 diabetes since the discovery of insulin.
This event is designed for anyone living with type 1 diabetes who would like to learn more about managing their wellbeing across a variety of contexts.
We provide a wealth of information and free resources to help you support and empower your patients or students.
Take our free course for schools to learn more about supporting pupils with type 1 diabetes in educational settings.
Home > News & events > News > JDRF-funded clinical trial drug slows type 1 diabetes in young people
An existing drug, called verapamil slowed the progression of type 1 diabetes in newly diagnosed children and adolescents in a clinical trial funded by JDRF. This breakthrough brings us closer to our goal of having disease-modifying therapies widely available for people with type 1 diabetes.
The clinical trial – known as the CLVer trial, published in this paper – found that a daily tablet of verapamil slowed the rate of insulin-producing beta cell destruction in young people newly diagnosed with type 1 a year after their diagnosis. This was measured by C-peptide levels, which were 30% higher in the group who were given verapamil than the control group who received a non-active placebo.
Dr Sanjoy Dutta, Chief Scientific Officer of JDRF International, said: “Safe, effective therapies are urgently needed to delay disease progression in people recently diagnosed with type 1 diabetes, an area of high priority for JDRF. The CLVer study is the second trial showing that verapamil, an inexpensive and widely used blood pressure medication, can preserve beta cells in the new onset period, making us one step closer to our goal of having disease-modifying therapies widely available for people with type 1 diabetes.”
The JDRF-funded researchers randomly split their young participants into two groups. One group received a verapamil pill to take once a day for a year and the other group took a daily placebo pill. The researchers calculated what dose of the drug to give each participant depending on their weight, so smaller children were given a lower dose.
Throughout the study, the participants gave blood samples to measure their HbA1c as well as taking two-hour mixed-meal tolerance tests to measure their C-peptide levels. The participants also wore continuous glucose monitors (CGMs) and the data from these was used to determine their percentage of time their blood glucose levels were in the target range.
The clinical trial involved 88 children aged 8 – 17 years. All participants started taking verapamil within 31 days of being diagnosed with type 1 diabetes.
The Ver-A-T1D Study – part of the JDRF-funded Type 1 Diabetes Immunotherapy Consortium is recruiting participants across England and Wales. To take part, you must be aged 18-44 years who were diagnosed with type 1 in the last six weeks. The study involves taking a verapamil tablet once a day for a year.
Access more information about Ver-A-T1D and get involved.
Verapamil is an existing drug used to treat high blood pressure. It is available on the NHS to treat heart conditions like angina (chest pain) and irregular heart rate by improving blood flow to the heart.
The researchers checked their participants’ blood pressure, heart health and liver function throughout the study as these are known side effects of verapamil. The researchers described the drug as ‘well tolerated’, meaning most of them didn’t experience any of these side effects.
In 2018, results were published showing verapamil increased C-peptide levels in a small clinical trial of adults newly diagnosed with type 1.
We have awarded the researchers a grant to monitor the participants in this trial for another three years to see if the benefits to C-peptide levels continue. We are also funding a researcher called Professor Colin Dayan in the UK to test whether giving people newly diagnosed with type 1 verapamil and teplizumab could be even more effective. Read more about Colin’s research project.
Clinical trials are an important part of research. They are how researchers make sure treatments are safe and effective. Find out more about what clinical trials are and how you can join one.
We focus on investing in research that will transform the lives of people with type 1 diabetes – improving treatments today until we find a cure.
Learn about the latest cutting-edge research that JDRF is funding to find better treatments and an eventual cure for type 1 diabetes.
The research, which was co-funded by JDRF, reveals that drugs that target the immune system offer very effective and rapid improvements in stabilising blood sugar levels, often within just three months.
Results from a clinical trial called the PROTECT study show that teplizumab can preserve beta cell function in children and adolescents newly diagnosed with type 1 diabetes.
Children in Northern Ireland are now eligible for a trial screening programme that will identify those at high risk of developing type 1 diabetes in the future.
Don’t miss out on the latest research, inspiring stories, tech news, upcoming events, and handy information on living well with type 1. Join us now and receive it all straight to your inbox.
It’s thanks to your dedication that we have funded great progress in type 1 cure, treatment and prevention research. Help us to continue our vital research.